Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin which is in Phase III clinical trials for the treatment of cutaneous leishmaniasis; and ATI-1701, which is a live-attenuated vaccine that is in preclinical trials for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.